Outset Medical, Inc. (NASDAQ:OM) Stock Has Average Price Target of $10.00 According to Analysts

Shares of Outset Medical, Inc. (NASDAQ:OM) have received a consensus rating of “Hold” from the five analysts that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $10.00.

Several analysts have issued reports on OM shares. Wall Street Zen raised Outset Medical from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Weiss Ratings cut Outset Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 21st.

Outset Medical Trading Down 3.8%

Shares of Outset Medical stock opened at $4.03 on Tuesday. The company’s fifty day simple moving average is $3.73 and its 200-day simple moving average is $4.16. The stock has a market capitalization of $75.76 million, a PE ratio of -0.99 and a beta of 1.99. Outset Medical has a 1-year low of $2.84 and a 1-year high of $13.28. The company has a debt-to-equity ratio of 1.03, a current ratio of 5.19 and a quick ratio of 4.11.

Outset Medical (NASDAQ:OM) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). Outset Medical had a negative net margin of 63.06% and a negative return on equity of 61.67%. The business had revenue of $31.64 million for the quarter, compared to the consensus estimate of $28.97 million. As a group, equities analysts anticipate that Outset Medical will post -3.81 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. BML Capital Management LLC raised its stake in Outset Medical by 250.2% during the 1st quarter. BML Capital Management LLC now owns 1,902,201 shares of the company’s stock worth $7,304,000 after acquiring an additional 1,359,021 shares during the period. Renaissance Technologies LLC lifted its holdings in Outset Medical by 391.3% during the first quarter. Renaissance Technologies LLC now owns 222,075 shares of the company’s stock valued at $853,000 after purchasing an additional 176,870 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Outset Medical by 4.1% during the first quarter. Bank of New York Mellon Corp now owns 62,360 shares of the company’s stock valued at $239,000 after purchasing an additional 2,435 shares in the last quarter. Marquette Asset Management LLC purchased a new position in Outset Medical during the second quarter valued at approximately $212,000. Finally, Sei Investments Co. boosted its position in shares of Outset Medical by 15.5% in the first quarter. Sei Investments Co. now owns 35,366 shares of the company’s stock worth $136,000 after purchasing an additional 4,738 shares during the period.

Outset Medical Company Profile

Outset Medical, Inc is a medical technology company that develops products for hemodialysis, a treatment that filters waste and excess fluid from the blood when the kidneys are no longer able to do so adequately. The company’s primary product is the Tablo Hemodialysis System, an integrated dialysis platform designed to simplify treatment for healthcare providers and support broader use of dialysis in hospitals, outpatient facilities and the home.

The Tablo system combines dialysis delivery, water purification and dialysate production in a single device and uses a touchscreen interface intended to guide users through treatment setup and operation.